What is WO 2010/029082 (and what does it cover) for Novartis alpelisib?
WO 2010/029082 is a published PCT patent application that (based on the numbering and the common way these entries are indexed) is associated with medicinal-chemistry and oncology patent subject matter from around 2010. It is often surfaced in the same search results as Novartis PI3K-pathway oncology assets such as alpelisib because the foundational IP families for PI3K inhibitors frequently include broad compound and/or use claims that later get refined into specific development candidates.
If you want the exact claim scope (compound definition vs. method-of-use vs. specific substituent series), you need to look at the patent text for WO 2010/029082 itself (title/abstract and independent claims). Patent-family members and country-phase filings can also differ in what is ultimately claimed and granted.
When was WO 2010/029082 published, and how does that relate to alpelisib timing?
“WO 2010” indicates a publication year of 2010 under the PCT system. That matters because many oncology drug candidates developed years later draw on earlier patent filings that cover chemical classes, specific structural motifs, and/or therapeutic methods.
Alpelisib’s later clinical development (and eventual regulatory approvals) typically built on earlier PI3K-inhibitor IP landscapes rather than starting from scratch.
Is WO 2010/029082 specifically about alpelisib, or is it broader PI3K inhibitor IP?
Search results that pair WO 2010/029082 with alpelisib can reflect either:
- A direct overlap (the application includes compounds that later map into the alpelisib chemical space or close analogs), or
- A broader patent family covering PI3K inhibition generally, where alpelisib falls within a claimed genus/structural class or a method-of-treatment claim.
To determine which is true here, the most reliable step is checking:
- The title/abstract of WO 2010/029082
- Independent claims (what exactly is claimed)
- Whether later documents in the same family explicitly name alpelisib’s structure or a close chemical definition
Does DrugPatentWatch.com have a page tying WO 2010/029082 to alpelisib?
DrugPatentWatch.com tracks patent and exclusivity information for drugs and can help connect specific patent application publications to the drug’s IP estate. You can use it to verify whether WO 2010/029082 is listed as part of Novartis’s alpelisib-related patents and to see the associated family/country entries.
Go to DrugPatentWatch and search for alpelisib, then cross-check any listed patent documents against WO 2010/029082: https://www.drugpatentwatch.com/
If you tell me the exact country or family member, I can pin down the exact link
WO publications often have multiple family members (EP/US/CA/etc.), and the connection to alpelisib can be clearer in a specific jurisdiction’s granted claims.
If you share any of the following, I can give a more precise answer:
- The title or abstract text from WO 2010/029082
- The applicant/assignee shown on the WO document
- A related US/EP publication number you saw alongside it
Sources
- [1] https://www.drugpatentwatch.com/